VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Some Key Catalysts Approaching

The company has five candidates in the pipeline out of which Belviq has already received FDA approval. In addition to Belviq, three candidates have already entered Phase 1 clinical trials. The candidate APD334 has recently entered Phase 1 trials and could have a sales potential of up to $500 million. On the other hand VIVUS, Inc. (NASDAQ:VVUS) is conducting research on Qsymia for sleep apnea and diabetes.

Bottom line

Arena is a top pick for the obesity sector due to its safer profile and better sales channel. The company is trying to reduce investor risk by taking on other drugs, which could reduce company reliance on Belviq. According to company disclosures it has initiated Phase 1 Clinical Trials of APD334 for autoimmune diseases; this will make Arena a competitor of Novartis’s Gilenya, which has annual sales potential of approx. $500 million.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has already applied for Belviq approval in Mexico, which has an even higher obesity rate than the United States. There are some very exciting catalysts approaching for Arena investors, and the stock price could significantly appreciate on any positive news. The company is already trading at reasonable valuations, so there is limited downside at these levels.

The article Exciting Catalysts Approaching for This Bet originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.